<DOC>
	<DOCNO>NCT00002707</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know chemotherapy give surgery effective without docetaxel give surgery breast cancer . PURPOSE : Randomized phase III trial compare effectiveness chemotherapy use doxorubicin cyclophosphamide without docetaxel treat woman stage II stage III breast cancer .</brief_summary>
	<brief_title>Chemotherapy Treating Women With Breast Cancer That Can Be Surgically Removed</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall disease-free survival patient operable adenocarcinoma breast treat 4 course preoperative doxorubicin cyclophosphamide ( AC ) alone v 4 course preoperative postoperative docetaxel ( TXT ) follow 4 course preoperative AC . II . Evaluate whether addition preoperative TXT preoperative AC result improve rate clinical pathologic locoregional tumor response . III . Assess whether addition preoperative TXT preoperative AC result improve rate breast conservation . IV . Assess whether postoperative TXT improve disease-free overall survival patient receive preoperative AC , especially certain subgroup patient ( e.g. , pathologically positive node ) . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( 50 vs 50 ) , clinical tumor size ( le 2.1 cm v 2.1-4.0 cm v great 4.0 cm ) , clinical nodal status ( negative v positive ) , participate center . Patients randomize one three treatment arm . Arm I : Patients receive doxorubicin IV follow cyclophosphamide IV 30 minute 2 hour day 1 every 21 day 4 course . Patients receive oral tamoxifen daily 5 year , start day 1 . After completion chemotherapy , patient offer surgery ( e.g. , lumpectomy axillary node dissection , modify radical mastectomy ) . Post-operative radiotherapy give post-lumpectomy . Arm II : Patients receive doxorubicin IV follow cyclophosphamide IV 30 minute 2 hour follow docetaxel IV 1 hour day 1 every 21 day 4 course . Patients receive oral tamoxifen daily 5 year , start day 1 . After completion chemotherapy , surgery offer ( arm I ) . Radiotherapy follow surgery post-lumpectomy patient . Arm III : Patients receive doxorubicin IV follow cyclophosphamide IV 30 minute 2 hour day 1 every 21 day 4 course . Patients receive oral tamoxifen daily 5 year , start day 1 . After completion chemotherapy , surgery offer ( arm I ) . After surgical recovery , docetaxel IV give 1 hour every 21 day 4 course . Radiotherapy follow docetaxel post-lumpectomy patient . Chemotherapy repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients follow every 6 month 5 year , annually thereafter . PROJECTED ACCRUAL : Approximately 2,400 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven invasive adenocarcinoma breast Fineneedle aspiration acceptable Core Trucut biopsy preferable No 63 day initial diagnosis randomization Tumor palpable clinical exam confine breast ipsilateral axilla If clinically negative axillary node ( N0 ) : primary tumor great 1 cm ( T1cT3 ) If clinically positive axillary node ( N1 ) : size primary tumor ( T13 ) No N2 disease , i.e. , ipsilateral node clinically fix one another structure No skeletal pain unless : Bone scan and/or roentgenologic exam negative metastatic disease Suspicious finding confirm benign xray , MRI , biopsy No ulceration , erythema , skin infiltration ( complete fixation ) , peau d'orange , skin edema magnitude Tethering dimple skin nipple inversion allow No bilateral malignancy Suspicious contralateral mass proven benign biopsy allow None follow unless prove benign biopsy : Suspicious palpable node contralateral axilla Palpable supraclavicular infraclavicular node Hormone receptor status : Any status PATIENT CHARACTERISTICS : Age : Any age Sex : Female Menopausal status : Not specify Performance status : Not specify Life expectancy : At least 10 year ( exclusive cancer diagnosis ) Hematopoietic : WBC least 4,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal AST/ALT normal Alkaline phosphatase normal Renal : Creatinine normal Cardiovascular : No active cardiac disease would preclude doxorubicin , e.g . : Documented myocardial infarction History congestive heart failure Angina pectoris require medication Valvular disease document cardiac function compromise Arrhythmia associate heart failure cardiac dysfunction Poorly control hypertension , i.e. , diastolic blood pressure great 100 mm Hg Cardiomegaly chest xray ventricular hypertrophy EKG unless leave ventricular ejection fraction least 45 % MUGA Other : No malignancy within past 10 year except : Segmentally resect lobular carcinoma situ ipsilateral contralateral breast Effectively treat nonmelanomatous skin cancer Surgically treat carcinoma situ cervix No systemic disease would preclude therapy No psychiatric addictive disorder would preclude informed consent Geographically accessible followup Not pregnant PRIOR CONCURRENT THERAPY : No prior therapy breast cancer No prior anthracyclines malignancy No concurrent sex hormone ( e.g. , birth control pills ovarian replacement therapy )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>